Cover Image
市場調查報告書

移植物抗宿主病 (GVHD):開發平台分析

Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 234335
出版日期 內容資訊 英文 397 Pages
訂單完成後即時交付
價格
Back to Top
移植物抗宿主病 (GVHD):開發平台分析 Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017
出版日期: 2017年04月28日 內容資訊: 英文 397 Pages
簡介

本報告提供移植物抗宿主病 (GVHD) 的治療方法之相關市場分析,提供您治療藥的開發·臨床實驗的最新趨勢,並彙整相關企業·組織簡介,開發中的產品,產業的最新趨勢等資訊。

簡介

  • 調查範圍

移植物抗宿主病 (GVHD) 概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

移植物抗宿主病 (GVHD):企業開發中的治療藥

移植物抗宿主病 (GVHD):大學/機關研究中的治療藥

移植物抗宿主病 (GVHD):開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

移植物抗宿主病 (GVHD):企業開發中的產品

移植物抗宿主病 (GVHD):大學/機關研究中的產品

移植物抗宿主病 (GVHD) 的治療藥開發企業

  • AbbVie Inc.
  • AbGenomics International, Inc.
  • Actelion Ltd
  • Adienne Pharma & Biotech
  • Alexion Pharmaceuticals, Inc.
  • Apceth GmbH & Co. KG
  • Athersys, Inc.
  • Bellicum Pharmaceuticals, Inc.
  • Bio-Cancer Treatment International Limited
  • Biogen, Inc.
  • Bristol-Myers Squibb Company
  • Caladrius Biosciences, Inc.
  • Cell2B S.A.
  • CytoDyn Inc.
  • Dr. Falk Pharma GmbH
  • Enlivex Therapeutics Ltd
  • Escape Therapeutics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Generon (Shanghai) Corporation Ltd.
  • GlaxoSmithKline Plc
  • Idera Pharmaceuticals, Inc.
  • ImmuNext, Inc.
  • Immunomedics, Inc.
  • Jazz Pharmaceuticals Plc
  • Kadmon Corporation, LLC
  • Kamada Ltd.
  • Kiadis Pharma B.V.
  • Kymab Limited MacroGenics, Inc.
  • Mesoblast Limited
  • Millennium Pharmaceuticals, Inc.
  • MSM Protein Technologies, Inc.
  • Neopharm Ltd.
  • Novartis AG
  • Omni Bio Pharmaceutical Inc.
  • Pharmicell Co., Ltd.
  • R-Tech Ueno, Ltd.
  • reguimyun
  • Rigel Pharmaceuticals, Inc.
  • Sarepta Therapeutics, Inc.
  • Seattle Genetics, Inc.
  • Sigmoid Pharma Limited
  • Spherium Biomed S.L.
  • Targazyme, Inc.
  • Therapix Biosciences Ltd
  • Tobira Therapeutics, Inc.
  • Xenikos B.V.

移植物抗宿主病 (GVHD):治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • abatacept
  • AbGn-168H
  • aldesleukin
  • Alecmestencel-L
  • Alpha-1 Antitrypsin
  • alpha-1 proteinase inhibitor (human)
  • ALXN-1007
  • anti-thymocyte globulin (rabbit)
  • Antibodies to Antagonize CD40L for Autoimmune Diseases and GVHD
  • Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease
  • ApoCell
  • ATIR-101
  • BCT-100
  • begelomab
  • Biologics for Graft Versus Host Disease
  • bortezomib
  • BPX-501
  • brentuximab vedotin
  • budesonide
  • cannabidiol
  • Cell Therapy for Autoimmune Diseases and GVHD
  • Cell Therapy for Graft Versus Host Disease
  • Cell Therapy for Graft Versus Host Disease
  • Cell Therapy for Graft Versus Host Disease
  • Cell Therapy for Graft versus Host Disease
  • Cell Therapy for Graft Versus Host Disease
  • Cell Therapy for Graft Versus Host Disease and Multiple Myeloma
  • cenicriviroc mesylate
  • CLBS-03
  • CRCBT-080004
  • cyclosporine IR + cyclosporine CR
  • CYP-001
  • defibrotide
  • Drugs for Acute and Chronic GVHD
  • erismodegib
  • F-652
  • Fc-Alpha-1 Antitrypsin
  • FcAAT-2
  • FcAAT-3
  • Ha-7
  • ibrutinib
  • ImmuneSafe
  • Immunocellgram for Graft Versus Host Disease
  • IMO-8400
  • inolimomab
  • IT-603
  • IT-901
  • KD-025
  • KY-1005
  • MesoStem
  • MGD-010
  • milatuzumab
  • Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases
  • MSM-707
  • MultiStem
  • natalizumab
  • Oligonucleotide to Inhibit NFAT1 for GVHD
  • panobinostat
  • ponesimod
  • Preimplantation Factor
  • PRO-140
  • Protein to Activate Toll-Like Receptor 5 for Infectious Disease and Graft Versus Host Disease
  • Recombinant HIV Gp120 Protein for GvHD And Autoimmune Disorders
  • Recombinant Protein to Antagonize CCR8 for Graft Versus Host Disease and Multiple Sclerosis
  • Recombinant Protein to Inhibit ILT3 for Graft Versus Host Disease
  • remestemcel-L
  • RGI-2001
  • RO-2959
  • RTU-009
  • Small Molecule for Graft Versus Host Disease, Hemophagocytic Lymphohistiocytosis and Autoimmune Disorders
  • Small Molecule to Inhibit Protein Kinase C Theta for Autoimmune Disorders
  • Small Molecules to Activate Telomerase for ALS, GVHD, Ageing and Leukemia
  • Small Molecules to Inhibit SHIP1 for Oncology and Immunology
  • SP-12008
  • Substance X
  • T-Guard
  • TZ-101

移植物抗宿主病 (GVHD):最近的開發平台趨勢

移植物抗宿主病 (GVHD):暫停中的計劃

移植物抗宿主病 (GVHD):開發中止的產品

移植物抗宿主病 (GVHD):產品開發的里程碑

  • 主要消息和新聞稿 (全10件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9192IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017, provides an overview of the Graft Versus Host Disease (GVHD) (Immunology) pipeline landscape.

Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms include abdominal pain or cramps, nausea, vomiting, and diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness and weight loss. Treatment includes immunosuppressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graft Versus Host Disease (GVHD) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 7, 23, 11, 35, 7 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 3, 13 and 2 molecules, respectively.

Graft Versus Host Disease (GVHD) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (GVHD) (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Graft Versus Host Disease (GVHD) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Graft Versus Host Disease (GVHD) (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Graft Versus Host Disease (GVHD) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (GVHD) (Immunology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Graft Versus Host Disease (GVHD) (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Graft Versus Host Disease (GVHD) (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Graft Versus Host Disease (GVHD) - Overview
  • Graft Versus Host Disease (GVHD) - Therapeutics Development
  • Graft Versus Host Disease (GVHD) - Therapeutics Assessment
  • Graft Versus Host Disease (GVHD) - Companies Involved in Therapeutics Development
  • Graft Versus Host Disease (GVHD) - Drug Profiles
  • Graft Versus Host Disease (GVHD) - Dormant Projects
  • Graft Versus Host Disease (GVHD) - Discontinued Products
  • Graft Versus Host Disease (GVHD) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Graft Versus Host Disease (GVHD), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by AbbVie Inc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by AbGenomics International Inc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Allergan Plc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Amunix Operating Inc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by AnaptysBio Inc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by apceth Biopharma GmbH, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Aptevo Therapeutics Inc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by arGEN-X BV, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Athersys Inc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Bellicum Pharmaceuticals Inc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Bio-Cancer Treatment International Ltd, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Biogen Inc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Capricor Therapeutics Inc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Cell2B Advanced Therapeutics SA, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by CellECT Bio Inc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Commence Bio Inc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Cynata Therapeutics Ltd, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Cytodyn Inc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Dr. Falk Pharma GmbH, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Escape Therapeutics Inc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Fate Therapeutics Inc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Generon (Shanghai) Corp Ltd, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Gilead Sciences Inc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Incyte Corp, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Jazz Pharmaceuticals Plc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Kadmon Corp LLC, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Kamada Ltd, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Kiadis Pharma NV, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Kymab Ltd, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by MacroGenics Inc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Mallinckrodt Plc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Mesoblast Ltd, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Nektar Therapeutics, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Nohla Therapeutics Inc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Novartis AG, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by OncoImmune Inc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by OSE Immunotherapeutics, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Pfizer Inc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Pharmicell Co Ltd, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by REGiMMUNE Corp, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Sanofi, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Sarepta Therapeutics Inc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Seattle Genetics Inc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Seres Therapeutics Inc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Sigmoid Pharma Ltd, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Synedgen Inc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Targazyme Inc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by TC BioPharm Ltd, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by TxCell SA, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by United BioPharma Inc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Vault Pharma Inc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by VBI Vaccines Inc, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by Xenikos BV, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by XL-protein GmbH, H1 2017
  • Graft Versus Host Disease (GVHD) - Pipeline by ZIOPHARM Oncology Inc, H1 2017
  • Graft Versus Host Disease (GVHD) - Dormant Projects, H1 2017
  • Graft Versus Host Disease (GVHD) - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Graft Versus Host Disease (GVHD) - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Graft Versus Host Disease (GVHD) - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Graft Versus Host Disease (GVHD) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Graft Versus Host Disease (GVHD), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top